Online Program

Return to main conference page

All Times EDT

Friday, June 5
Practice and Applications
Practice and Applications Posters, Part 2
Fri, Jun 5, 2:00 PM - 5:00 PM
TBD
 

Data-Driven Statistical Modeling and Analysis of the Survival Times of Multiple Myeloma Cancer (308451)

*Lohuwa Mamudu, University of South Florida 
Christ P Tsokos, University of South Florida 

Keywords: Data driven; Multiple myeloma; Statistical modeling ; Health science

MultipleMyeloma (MM) has been and continues to be the subject of many research studies. The main goal is to improve the therapeutic/treatment process of survival of MM patients. Based on the 2012-2016 MM cases and deaths, the number of new cases was 6.9 per 100,000 men and women per year, and the number of deaths was 3.3 per 100,000 men and women per year. It is therefore imperative to research into MM. In the present study, we proposed a data-driven statistical model for the survival time of 48 patients diagnosed with multiple myeloma as a function of 16 attributable risk factors. We identified 9 attributable risk factors out of 16 and one interaction term to be significantly contributing to the survival time. They are Bence Jone protein in urine, blood urea nitrogen (BUN)/serum creatinine, infections, % myeloid cells in peripheral blood, fractures, serum calcium, gender, platelets and age, and white blood cells & total serum protein an interaction term. The proposed model satisfied all the model assumptions, passes the residual analysis test and has very high prediction accuracy. Thus, it passes the goodness-of-fit test and the qualities of a good model. The identified significant attributable risk factors and the interaction has been ranked based on the percent contribution to the survival time. The proposed model was evaluated and compared with other existing models of survival of multiple myeloma. Our model is very accurate and also identifies some new significant risk factors. The study offers an improved strategy for the therapeutic/treatment process of multiple Myeloma Cancer.